Talk:Novartis

This is the talk page for discussing improvements to the Novartis article. This is not a forum for general discussion of the subject of the article.

Put new text under old text. Click here to start a new topic. New to Wikipedia? Welcome! Learn to edit; get help. Assume good faith Be polite and avoid personal attacks Be welcoming to newcomers Seek dispute resolution if needed Article policies Neutral point of view No original research Verifiability

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL

Archives: 1Auto-archiving period: 2 months

This  level-5 vital article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects:

Companies Top‑importance Companies portal This article is within the scope of WikiProject Companies, a collaborative effort to improve the coverage of companies on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks. Top This article has been rated as Top-importance on the project's importance scale. WikiProject Companies To-do: Here are some tasks awaiting attention: Article requests : Wikipedia:Requested articles/Business and economics/Companies Assess : Category:Unassessed company articles Copyedit : Category:Company articles needing attention Infobox : Category:Company articles needing infoboxes Maintain : Portal:Companies Stubs : Help expand stub articles located at Category:Company stubs Other : Tag company articles with the {{portal|Companies}} template Tag company talk pages with the {{WikiProject Companies}} project banner Answer requests for comments Pharmacology High‑importance This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks. High This article has been rated as High-importance on the project's importance scale. Switzerland High‑importance Switzerland portal This article is within the scope of WikiProject Switzerland, a collaborative effort to improve the coverage of Switzerland on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks. High This article has been rated as High-importance on the project's importance scale.

The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE. Rusoke365 (talk · contribs) has been paid by Novartis on their behalf. Their editing has included contributions to this article.

Billions in lost health care dollars with entresto, no evidence sacubitril does anything

Prominent physician researchers have cried foul over entresto approval from the beginning, a harvard professor is behind it too as founder of the so called novartis institute for biomedical research. The scale of this grift is unbelievable. Check out the new head of the FDA's biologics division explicit reviews of entresto on his youtube channel (denmark lectures, bad drug approval in the USA), it's so sad people around the world are so easily fooled this way.

Novartis ripped off our medicare system for billions of dollars, sorry it's true — Preceding unsigned comment added by Steve Brackett (talk • contribs) 04:42, 17 September 2025 (UTC)[reply]

it's bad enough they steal from the sick this way but they actually had UofM and UofF take them to court over ripping off their intellectual property. Even more astounding, they are before the courts trying to block a generic version of a drug that is nothing more than a generic to begin with. It's just unbelievable, welcome to silly world. check out ATPscam.com

https://hcrenewal.blogspot.com/2015/07/entresto-blockbuster-or-just-over-hyped.html Steve Brackett (talk) 03:35, 17 September 2025 (UTC)[reply]